# Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension

Study · id `cardio:ct-nct06041529` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06041529](<https://clinicaltrials.gov/study/NCT06041529>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06041529

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 198 participants.

## Technical summary

Registry record NCT06041529. Randomized; no masking; primary purpose treatment. Start 2023-10-18 (actual); primary completion 2026-02-28 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 198 participants (enrolled count; ClinicalTrials.gov record NCT06041529, source copy `cardio:ctgov-nct06041529-2026-02-13`, retrieved 2026-10-26)
- Started: 2023-10-18 (actual) (ClinicalTrials.gov record NCT06041529, source copy `cardio:ctgov-nct06041529-2026-02-13`, retrieved 2026-10-26)
- Primary completion: 2026-02-28 (anticipated) (ClinicalTrials.gov record NCT06041529, source copy `cardio:ctgov-nct06041529-2026-02-13`, retrieved 2026-10-26)
- Completion: 2026-02-28 (anticipated) (ClinicalTrials.gov record NCT06041529, source copy `cardio:ctgov-nct06041529-2026-02-13`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT06041529, source copy `cardio:ctgov-nct06041529-2026-02-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06041529-2026-02-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension
- Condition: Essential Hypertension
- Intervention (Drug): Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg
- Intervention (Drug): Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mg
- Lead sponsor: Yuhan Corporation
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Yuhan Corporation (`cardio:org-yuhan-corporation`)

## Provenance

Content hash: c0d0f47061eefa964800a0cb692b1ed56f1aeaf65b115e38adcccc4254eea4d6
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
